Retrieve available abstracts of 56 articles: HTML format
Single Articles
May 2025
BAHARDOUST M, Yarahmadi D, Aghakhani Z, Mahdi Kakoienejad M, et al Comparison of short-term treatment with atorvastatin versus rosuvastatin for
preventing contrast-associated acute kidney injury in patients undergoing
coronary angiography/percutaneous coronary intervention: a systematic review and
meta-analysis.
J Cardiovasc Pharmacol. 2025 May 14. doi: 10.1097/FJC.0000000000001718. PubMedAbstract available
BURNETT H, Cichewicz A, Natani H, Bhowmik D, et al Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With
Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network
Meta-Analysis.
J Cardiovasc Pharmacol. 2025 May 13. doi: 10.1097/FJC.0000000000001712. PubMedAbstract available
April 2025
ZHANG C, Du Z, Chen R, Liu X, et al Gene- and cell-based therapy in cardiovascular diseases.
J Cardiovasc Pharmacol. 2025 Apr 30. doi: 10.1097/FJC.0000000000001707. PubMedAbstract available
CAPPANNOLI L, Fracassi F, Aurigemma C, Romagnoli E, et al COLCHICINE IN ACUTE CORONARY SYNDROMES: A META-ANALYSIS OF 12.602 PATIENTS.
J Cardiovasc Pharmacol. 2025 Apr 28. doi: 10.1097/FJC.0000000000001706. PubMedAbstract available
ABBATE A, Biondi-Zoccai G, Altara R, Booz GW, et al Changes for 2025 at Journal of Cardiovascular Pharmacology: Introducing Our
Junior Associate Editors, Podcasts, Feature, and New Board Members.
J Cardiovasc Pharmacol. 2025;85:239-242. PubMed
March 2025
SADEGHIPOUR P, Talasaz AH, Rashedi S, Jamalkhani S, et al A Multifaceted Intervention to Mitigate the Adverse Cardiovascular Effects of Air
Pollution: A Feasibility Randomized Controlled Trial.
J Cardiovasc Pharmacol. 2025 Mar 18. doi: 10.1097/FJC.0000000000001691. PubMedAbstract available
February 2025
BIONDI-ZOCCAI G, Weber BN, Abbate A, Booz GW, et al Cardiac Immunotherapy, Immuno-Cardiology and the Future of Cardiovascular
Pharmacology.
J Cardiovasc Pharmacol. 2025 Feb 27. doi: 10.1097/FJC.0000000000001687. PubMedAbstract available
GRAGNANO F, Calabro P, Angiolillo DJ Deciphering the Role of In-hospital Bleeding in Acute Coronary Syndromes.
J Cardiovasc Pharmacol. 2025 Feb 17. doi: 10.1097/FJC.0000000000001685. PubMed
PEPE M, Tritto R, Napoli G, Giordano S, et al Role of Indobufen in coronary artery disease: the story of a neglected drug. A
systematic review.
J Cardiovasc Pharmacol. 2025 Feb 11. doi: 10.1097/FJC.0000000000001681. PubMedAbstract available
SPADAFORA L, Betti M, D'Ascenzo F, De Ferrari G, et al Impact of In-Hospital Bleeding on Post-Discharge Therapies and Prognosis in Acute
Coronary Syndromes.
J Cardiovasc Pharmacol. 2025 Feb 10. doi: 10.1097/FJC.0000000000001678. PubMedAbstract available
ZHANG K, He C, Tong Y, He Y, et al Relationship between ALDH2 Gene Polymorphism and Vasodilative Effect of
Nitroglycerin on Coronary Arteries.
J Cardiovasc Pharmacol. 2025 Feb 10. doi: 10.1097/FJC.0000000000001682. PubMedAbstract available
GALATI G, Germanova O Mineralocorticoid receptor antagonists in end-stage renal disease under renal
replacement therapies: bridging the gap between cardiovascular and systemic
benefit, from heart failure to myocardial infarction.
J Cardiovasc Pharmacol. 2025 Feb 6. doi: 10.1097/FJC.0000000000001677. PubMed
ZHAO C, Fu J, Wang Y, Zhou Y, et al Latest evidence and perspectives of Panax notoginseng extracts and preparations
for the treatment of cardiovascular diseases: a review.
J Cardiovasc Pharmacol. 2025 Feb 4. doi: 10.1097/FJC.0000000000001670. PubMedAbstract available
January 2025
BONAVENTURA A, Potere N, Liberale L, Kraler S, et al Colchicine in coronary artery disease: Where do we stand?
J Cardiovasc Pharmacol. 2025 Jan 23. doi: 10.1097/FJC.0000000000001672. PubMed
BIONDI-ZOCCAI G, Frati G, Peruzzi M, Bernardi M, et al Patient reported outcome measures in cardiovascular research and care: PRO(M)s
and CONS.
J Cardiovasc Pharmacol. 2025 Jan 23. doi: 10.1097/FJC.0000000000001669. PubMedAbstract available
ABBATE A, Biondi-Zoccai G, Altara R, Booz GW, et al Changes for 2025 at Journal of Cardiovascular Pharmacology: Introducing Our
Junior Associate Editors, Podcasts, Feature, and New Board Members.
J Cardiovasc Pharmacol. 2025 Jan 21. doi: 10.1097/FJC.0000000000001673. PubMed
ANTO S, Sun C, O'Rourke ST Activation of APJ Receptors by CMF-019, But Not Apelin, Causes
Endothelium-Dependent Relaxation of Spontaneously Hypertensive Rat Coronary
Arteries.
J Cardiovasc Pharmacol. 2025 Jan 21. doi: 10.1097/FJC.0000000000001671. PubMedAbstract available
SADLER M, Madaudo C, Cannata A, Bromage D, et al IL-1 blockade in myocardial infarction and its efficacy in patients with complex
coronary artery disease. Another brick in the wall.
J Cardiovasc Pharmacol. 2025 Jan 2. doi: 10.1097/FJC.0000000000001666. PubMed
December 2024
JALLORINA A, Vij K, Wan L, Thomas J, et al A Decadal Exploration of Cutaneous Adverse Effects of FDA-Approved Cardiovascular
Medications: Insights from 2013 to 2023.
J Cardiovasc Pharmacol. 2024 Dec 5. doi: 10.1097/FJC.0000000000001660. PubMedAbstract available
ABBATE A, Van Tassell B, Bogin V, Markley R, et al Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment
Elevation Myocardial Infarction: Secondary End Points From an International,
Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study.
J Cardiovasc Pharmacol. 2024;84:565-577. PubMedAbstract available
November 2024
YANJUAN L, Shuangyou D, Ying W, Xing C, et al The research progress: Cuproptosis and copper metabolism in regulating
cardiovascular diseases.
J Cardiovasc Pharmacol. 2024 Nov 15. doi: 10.1097/FJC.0000000000001653. PubMedAbstract available
DENICOLAI M, Morello M, Golino M, Corna G, et al Interleukin-1 Blockade in Patients With ST-Segment Elevation Myocardial
Infarction Across the Spectrum of Coronary Artery Disease Complexity.
J Cardiovasc Pharmacol. 2024 Nov 12. doi: 10.1097/FJC.0000000000001652. PubMedAbstract available
GU N, Chen P, Wang X, Shen C, et al Association Between the Neutrophil-to-Lymphocyte Ratio and in-Stent
Neoatherosclerosis and Plaque Vulnerability: An Optical Coherence Tomography
Study.
J Cardiovasc Pharmacol. 2024;84:506-514. PubMedAbstract available
October 2024
TIAN RZ, Zhuang DL, Vong CT, He X, et al Role of autophagy in myocardial remodeling after myocardial infarction.
J Cardiovasc Pharmacol. 2024 Oct 25. doi: 10.1097/FJC.0000000000001646. PubMedAbstract available
RUBAIY HN Canonical Transient Receptor Potential (TRPC) Channels in Cardiovascular
Pathology and their Modulators.
J Cardiovasc Pharmacol. 2024 Oct 15. doi: 10.1097/FJC.0000000000001643. PubMedAbstract available
ABBATE A, Van Tassell B, Bogin V, Markley R, et al Interleukin-1 blockade with RPH-104 (goflikicept) in patients with ST-segment
elevation myocardial infarction (STEMI): secondary endpoints from an
international, double blind, randomized, placebo-controlled, phase IIa study.
J Cardiovasc Pharmacol. 2024 Oct 2. doi: 10.1097/FJC.0000000000001635. PubMedAbstract available
September 2024
RUSSO F, Palma A, Cacciatore S, Tomarelli E, et al Rethinking beta-blockers after ST-elevation myocardial infarction: essential for
some, questionable for others.
J Cardiovasc Pharmacol. 2024 Sep 6. doi: 10.1097/FJC.0000000000001632. PubMed
HUANG HM, Ran FY, Chen J, Shen YS, et al Outcomes of Ticagrelor Versus High-dose Clopidogrel in CYP2C19 Intermediate
Metabolizer Undergoing Percutaneous Coronary Intervention for Acute Coronary
Syndromes.
J Cardiovasc Pharmacol. 2024;84:347-355. PubMedAbstract available
LI YY, Zhong XJ, Luo JT, Zeng CM, et al Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary
Intervention: A Single-Center Randomized Trial in China.
J Cardiovasc Pharmacol. 2024;84:331-339. PubMedAbstract available
BABIKER F, Al-Kouh A Immunoglobulin-Mediated Cardiac Protection From Ischemia/Reperfusion Injury in
Diabetic Rats Is Associated With Endothelial Nitric Oxide Synthase/Glucose
Transporter-4 Signaling Pathway.
J Cardiovasc Pharmacol. 2024;84:319-330. PubMedAbstract available
August 2024
GIANNINO G, Giacobbe F, Annone U, Ravetti E, et al Impact of adherence to beta-blockers in all-comers ST-segment elevation
myocardial infarction (STEMI) patients and according to left ventricular ejection
fraction (LVEF) at discharge: results from the real-world registry FAST-STEMI.
J Cardiovasc Pharmacol. 2024 Aug 29. doi: 10.1097/FJC.0000000000001627. PubMedAbstract available
SHI J, Guan B, Gong M, He X, et al Kirenol alleviates inflammation and oxidative stress to improve myocardial
ischemia/reperfusion injury in rats.
J Cardiovasc Pharmacol. 2024 Aug 22. doi: 10.1097/FJC.0000000000001626. PubMedAbstract available
DEL BUONO MG, La Vecchia G, D'Aiello A, Pedicino D, et al Clinical Characteristics, Management, and Outcomes in Cardiogenic Shock: Insights
From a High-Volume Italian Cardiac Intensive Care Unit.
J Cardiovasc Pharmacol. 2024;84:210-219. PubMedAbstract available
RUSSO V, Fabiani D, Imbalzano E, De Michele M, et al Clinical Performance and Persistence on Dual Pathway Inhibition with Rivaroxaban
and Aspirin in Real-World Setting.
J Cardiovasc Pharmacol. 2024;84:170-174. PubMedAbstract available
DENG HW, Ye ZM, Hu RT, Qin C, et al The Role of Long Noncoding RNAs in Vascular Smooth Muscle Cell Phenotype and the
Pathogenesis of Cardiovascular and Cerebrovascular Aneurysms.
J Cardiovasc Pharmacol. 2024;84:125-135. PubMedAbstract available
July 2024
DEL BUONO MG, La Vecchia G, Angiolillo DJ Antithrombotic treatment regimens in patients undergoing percutaneous coronary
revascularization requiring oral anticoagulation: what real-world evidence shows
us.
J Cardiovasc Pharmacol. 2024 Jul 29. doi: 10.1097/FJC.0000000000001619. PubMed
WRIGHT CX, Feher A From Risk to Resilience: improved outcomes after myocardial infarction in
patients with Sjogren's syndrome.
J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001615. PubMed
ZHANG J, Xiong X, Li J, Luo C, et al Valtrate suppresses TNFSF14-mediated arrhythmia after myocardial
ischemia-reperfusion via inducing N-linked glycosylation of LTbetaR to regulate
MGA/MAX/c-Myc/Cx43.
J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001613. PubMedAbstract available
SCIAHBASI A, De Rosa S, Gargiulo G, Giacoppo D, et al Management of patients treated with oral anticoagulant therapy undergoing
percutaneous coronary intervention with stent implantation: the PERSEO Registry.
J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001607. PubMedAbstract available
LINGYAN Z, Zijia H, Ya Z, Ying Z, et al Cardiovascular outcomes of SGLT-2 Inhibitors Across BMI Spectrum in Heart Failure
Patients: An Updated Systematic Review and Meta-Analysis.
J Cardiovasc Pharmacol. 2024 Jul 8. doi: 10.1097/FJC.0000000000001610. PubMedAbstract available
KARAKASIS P, Patoulias D, Giannakoulas G, Fragakis N, et al Are We Ready for Expanding the Use of Sodium-Glucose Cotransporter-2 Inhibitors
in Patients With Acute Myocardial Infarction?
J Cardiovasc Pharmacol. 2024;84:26-28. PubMed
ZHANG X, Sun G, Li Z, Gao W, et al Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Acute
Myocardial Infarction With or Without Type 2 Diabetes: A Systematic Review and
Meta-analysis.
J Cardiovasc Pharmacol. 2024;84:18-25. PubMedAbstract available
SIKORSKA M, Chmiel J, Papuga-Szela E, Broniatowska E, et al Apixaban Versus Vitamin K Antagonists in Patients With Antiphospholipid Syndrome:
A Cohort Study.
J Cardiovasc Pharmacol. 2024;84:36-44. PubMedAbstract available
June 2024
HSIAO BY Sjogren syndrome and outcomes of acute myocardial infarction: A propensity-score
matched analysis of the Nationwide Inpatient Sample 2005-2018.
J Cardiovasc Pharmacol. 2024 Jun 19. doi: 10.1097/FJC.0000000000001603. PubMedAbstract available
BRUOHA S, Galli M, Sabouret P, Yosefy C, et al Atherosclerotic Plaque Erosion: Mechanisms, Clinical Implications, and Potential
Therapeutic Strategies-A Review.
J Cardiovasc Pharmacol. 2024;83:547-556. PubMedAbstract available
ZHANG W, Zhang W, Gu N, Qiu Z, et al Naturally Occurring Atherosclerosis Progression and In-stent Restenosis:
Exploring Histomorphologic Associations Using Optical Coherence Tomography.
J Cardiovasc Pharmacol. 2024;83:646-654. PubMedAbstract available
May 2024
ROMEO FJ Dual Pathway Inhibition in Stable Cardiovascular Disease: It Takes Two to Tango!
J Cardiovasc Pharmacol. 2024 May 31. doi: 10.1097/FJC.0000000000001599. PubMed
HU D, Qin D, Kuang J, Yang Y, et al Metformin-induced PCSK9 inhibition further decreases LDL-C following statin
treatment in patients with coronary artery disease and without diabetes.
J Cardiovasc Pharmacol. 2024 May 21. doi: 10.1097/FJC.0000000000001592. PubMedAbstract available
LUZ DE CASTRO A, Ortiz VD, Hickmann AR, Lacerda DS, et al EFFECTS OF PTEROSTILBENE ON HEART AND LUNG OXIDATIVE STRESS PARAMETERS IN TWO
EXPERIMENTAL MODELS OF CARDIOVASCULAR DISEASE: MYOCARDIAL INFARCTION AND
PULMONARY ARTERIAL HYPERTENSION.
J Cardiovasc Pharmacol. 2024 May 4. doi: 10.1097/FJC.0000000000001572. PubMedAbstract available
ZANG G, Chen Y, Guo G, Wan A, et al Protective Effect of CD137 Deficiency Against Postinfarction Cardiac Fibrosis and
Adverse Cardiac Remodeling by ERK1/2 Signaling Pathways.
J Cardiovasc Pharmacol. 2024;83:446-456. PubMedAbstract available
April 2024
LU B, Feng Z, Wang Y, Liao J, et al N-n-butyl haloperidol iodide mitigates myocardial ischemia/reperfusion injury
through activation of SIRT1-Nrf2 signaling loop.
J Cardiovasc Pharmacol. 2024 Apr 2. doi: 10.1097/FJC.0000000000001550. PubMedAbstract available
ZHANG M, Peng W, Yin S, Zhao Y, et al Nondual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Before
Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis.
J Cardiovasc Pharmacol. 2024;83:297-305. PubMedAbstract available
March 2024
SIMEONE B, Rocco E, Biondi-Zoccai G, Versaci F, et al N-Acetylcysteine: The Next Best Thing for Cardiovascular Interventions and
Surgery?
J Cardiovasc Pharmacol. 2024 Mar 14. doi: 10.1097/FJC.0000000000001558. PubMed
GAO L, Wang Q, Li MY, Zhang MM, et al A mechanism for the treatment of cardiovascular and renal disease.
J Cardiovasc Pharmacol. 2024 Mar 14. doi: 10.1097/FJC.0000000000001562. PubMedAbstract available
MARTINEZ NAYA N, Toldo S, Abbate A Colchicine Leads the Charge in Post-percutaneous Coronary Intervention
Anti-inflammatory Defense.
J Cardiovasc Pharmacol. 2024;83:231-233. PubMed
February 2024
RT W Oral Oncolytics and Cardiovascular Risk Management and Monitoring: Erratum.
J Cardiovasc Pharmacol. 2024 Feb 15. doi: 10.1097/FJC.0000000000001500. PubMed